The antiphospholipid syndrome.
Jerrold S Levine, D Ware Branch, Joyce Rauch
https://pubmed.ncbi.nlm.nih.gov/11882732/Actively Recruiting
Led by Duke University · Updated on 2026-05-29
2800
Participants Needed
1
Research Sites
N/A
Total Duration
Antiphospholipid antibody syndrome APS is an autoimmune condition that increases the risk of blood clots in veins or arteries, along with recurrent miscarriages. APS can occur alone primary APS or with other autoimmune diseases like lupus secondary APS. Researchers are exploring the genetic factors that might increase the risk of developing APS by studying people with APS who have family members affected by APS or other autoimmune disorders such as lupus or rheumatoid arthritis. This observational study gathers genetic and clinical information from participants with APS and their families. Participants may complete phone questionnaires, provide detailed family and medical histories, and give blood samples for antibody testing and DNA analysis. Blood samples can be collected at study sites or convenient locations if participants cannot visit the site. Results will compare genetic risk factors between families with APS and families with other autoimmune diseases. Participants will share medical and family history, undergo blood testing, and provide information on co-existing conditions, medication use, and pregnancy history. Researchers will analyze this data to identify genetic links associated with APS. The study aims to improve understanding of APS genetics over its duration. Participation involves questionnaires, interviews, and blood sample collection, with some visits conducted remotely by phone.
CONDITIONS
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome
T
Thomas L. Ortel, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Duke University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person or phone)
Duration - Varies depending on participant availability
Participants provide detailed family and medical history and blood samples for genetic and antibody analysis.
1 visit (in-person or remote) for history and blood sample collection
Duration - Up to study completion in March 2029
Participants' clinical and genetic data are observed and compared to understand genetic risk factors for APS.
No scheduled visits; data collected through records and questionnaires
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Jerrold S Levine, D Ware Branch, Joyce Rauch
https://pubmed.ncbi.nlm.nih.gov/11882732/Ricard Cervera, Jean-Charles Piette, Josep Font...
https://pubmed.ncbi.nlm.nih.gov/11953980/Thomas L Ortel
https://pubmed.ncbi.nlm.nih.gov/16475047/R Hal Scofield, Gail R Bruner, Jennifer A Kelly...
https://pubmed.ncbi.nlm.nih.gov/12393658/Jennifer A Kelly, Kevin Thompson, Jeff Kilpatrick...
https://pubmed.ncbi.nlm.nih.gov/12192084/Duke University
Lead Sponsor